Lithium Hydroxide → HCID 178445687, compound

Participants

Reaction Steps

Butyl 1-{(trans-4-tert-butylcyclohexyl)[4-(trifluoromethoxy)benzoyl]amino}indane-5-carboxylate, enantiomer A (50 mg) or enantiomer B (70 mg), was saponified with aqueous LiOH and then coupled to 5-amino tetrazole following the procedure described (Step D., Example 1/2) to give 1-{(trans-4-tert-butylcyclohexyl)[4-(trifluoromethoxy)benzoyl]amino}-N-1H-tetrazol-5-ylindane-5-carboxamide. Enantiomer A: HPLC/MS: m/z=571.2 (M+1), Rt=2.65 min. 1H NMR (DMSO-d6): δ 12.34 (1H, br s), 7.95 (1H, s), 7.90 (1H, d, J=8.0 Hz), 7.52 (2H, d, J=8.0 Hz), 7.44 (2H, d, J=8.0 Hz), 7.35 (1H, d, J=8.0 Hz), 5.05 (1H, m), 3.35 (1H, m), 3.15 (1H, m), 2.96 (1H, m), 2.55 (1H, m), 2.36 (1H, m), 2.12 (1H, m), 1.77 (6H, m), 0.99 (1H, m), 0.84 (1H, m), 0.79 (9H, s). Enantiomer B: HPLC/MS and 1H NMR (DMSO-d6) are identical to those of enantiomer A.

Provenance & Evidence